Citizens Financial Group Inc. RI Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Citizens Financial Group Inc. RI increased its stake in Eli Lilly and Company by 4.5%, now owning 56,465 shares valued at approximately $46.6 million.
• Eli Lilly has recently declared a quarterly dividend of $1.50, representing an annualized dividend yield of 0.8%.
• Analysts show mixed ratings on Eli Lilly, with the average target price set at $1,012.56 amid varying recommendations from firms like Morgan Stanley and HSBC.

Citizens Financial Group Inc. RI boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,465 shares of the company's stock after buying an additional 2,418 shares during the quarter. Eli Lilly and Company makes up approximately 0.9% of Citizens Financial Group Inc. RI's investment portfolio, making the stock its 22nd biggest holding. Citizens Financial Group Inc. RI's holdings in Eli Lilly and Company were worth $46,635,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Garner Asset Management Corp grew its holdings in Eli Lilly and Company by 2.3% in the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Orion Capital Management LLC raised its stake in Eli Lilly and Company by 2.5% in the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock valued at $1,243,000 after buying an additional 40 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG boosted its holdings in Eli Lilly and Company by 4.1% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after acquiring an additional 2,568 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $106.20 during midday trading on Thursday, hitting $640.17. The company's stock had a trading volume of 26,056,463 shares, compared to its average volume of 3,684,957. The company has a market cap of $606.71 billion, a P/E ratio of 52.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $633.20 and a 12-month high of $972.53. The business's 50 day simple moving average is $776.36 and its 200 day simple moving average is $799.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday. UBS Group cut their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Guggenheim increased their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $999.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.